DI-METREX
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DI-METREX (DI-METREX).
Combination of diphenhydramine (H1-antagonist) and pseudoephedrine (alpha-1 agonist). Diphenhydramine blocks histamine at H1 receptors, reducing allergic symptoms; pseudoephedrine causes vasoconstriction via alpha-1 adrenergic receptors, relieving nasal congestion.
| Metabolism | Diphenhydramine: extensively metabolized via CYP2D6 to inactive metabolites; pseudoephedrine: partially metabolized in liver via N-demethylation to active metabolite (norpseudoephedrine) and excreted unchanged in urine. |
| Excretion | Renal excretion accounts for approximately 70% of elimination as unchanged drug and metabolites; biliary/fecal excretion accounts for the remaining 30%. |
| Half-life | The terminal elimination half-life is approximately 12 hours, requiring twice-daily dosing for steady-state concentrations. |
| Protein binding | Approximately 85% bound to serum albumin. |
| Volume of Distribution | Vd is 0.8 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 90% due to minimal first-pass metabolism. |
| Onset of Action | Oral administration: 30-60 minutes; intravenous administration: immediate clinical effect observed within minutes. |
| Duration of Action | Duration is approximately 8-12 hours after a single dose, supporting twice-daily dosing intervals. |
| Molecular Weight | 465.96 |
4 mg orally once daily, increased to a maximum of 8 mg once daily if needed.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: 2 mg once daily. GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: 2 mg once daily. Child-Pugh C: not recommended. |
| Pediatric use | Not established; contraindicated in children under 12 years. |
| Geriatric use | Start at 2 mg once daily; titrate cautiously due to increased risk of hypotension and cognitive effects. |
| 1st trimester | Contraindicated; risk of renal toxicity in fetus. |
| 2nd trimester | Contraindicated; may cause fetal harm. |
| 3rd trimester | Contraindicated; may cause neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for DI-METREX (DI-METREX).
| Placental transfer | Crosses placenta; documented in animal studies. |
| Breastfeeding | Excreted in breast milk; avoid breastfeeding due to potential for serious adverse reactions in nursing infants. |
| Lactation Rating | L5 - Contraindicated |
■ FDA Black Box Warning
Not applicable (no FDA boxed warning).
| Serious Effects |
PregnancyBreastfeedingRenal impairmentHypersensitivity to drug or class
| Precautions | Do not use in patients with severe hypertension or coronary artery disease; caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and MAOI use; avoid exceeding recommended dose due to risk of serious cardiovascular events; may cause drowsiness or excitability in children. |
| Food/Dietary | Avoid alcohol entirely. Folic acid supplementation is often prescribed to reduce side effects; do not take any other folate supplements without approval. Caffeine may slightly increase absorption, but no specific dietary restrictions. Maintain adequate hydration to help prevent kidney toxicity. |
Loading safety data…
| Teratogenic Risk | DI-METREX (metformin) is classified as FDA Pregnancy Category B. First trimester: No increased risk of major congenital anomalies observed in human studies; some studies suggest reduced risk of neural tube defects in women with PCOS. Second and third trimesters: Risk of neonatal hypoglycemia and macrosomia reduced compared to untreated diabetes; no evidence of teratogenicity. Overall, benefits of glycemic control outweigh potential risks. |
| Fetal Monitoring | Monitor maternal renal function (serum creatinine, eGFR) at baseline and periodically. Assess glycemic control (fasting and postprandial glucose, HbA1c). Monitor fetal growth and anatomy via ultrasound due to underlying diabetes or PCOS. Watch for signs of lactic acidosis (rare) if renal function deteriorates. |
| Fertility Effects | In women with PCOS, metformin improves ovulation rates and menstrual regularity, enhancing fertility. In diabetic women, improved glycemic control may reduce pregnancy loss and complications. No direct adverse effects on male fertility reported. |
| Clinical Pearls | DI-METREX (methotrexate) has a long half-life; monitor for cumulative toxicity. Administer folic acid supplementation to reduce gastrointestinal and hematologic side effects. Use with caution in patients with ascites or pleural effusions, as drug accumulation can occur. Premedication with NSAIDs increases methotrexate toxicity. Always check liver function tests and renal function before each dose. |
| Patient Advice | Take methotrexate exactly as prescribed, usually once weekly, not daily. Serious harm can occur if taken daily. · Avoid alcohol completely to reduce liver damage risk. · Report any unusual bleeding, bruising, fever, mouth sores, or persistent cough immediately. · Do not take any other medications, including over-the-counter and herbal products, without first consulting your doctor. · Use effective contraception; methotrexate can cause severe birth defects. |